

PRIOR AUTHORIZATION CRITERIA

DRUG CLASS CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR ANTAGONISTS
INJECTABLE, INTRAVENOUS INFUSION

BRAND NAME*
(generic)

AIMOVIG
(erenumab-aooe injection)

AJOVY
(fremanezumab-vfrm injection)

EMGALITY
(galcanezumab-gnlm injection)

VYEPTI
(eptinezumab-jjmr injection, for intravenous use)

Status: CVS Caremark® Criteria
Type: Initial Prior Authorization with Quantity Limit

Ref # 2581-C
Ref # REG 3160-C

* Drugs that are listed in the target drug box include both brand and generic and all dosage forms and strengths unless otherwise stated. OTC products are not included unless otherwise stated.

FDA-APPROVED INDICATIONS

Aimovig

Aimovig is indicated for the preventive treatment of migraine in adults.

Ajovy

Ajovy is indicated for the preventive treatment of migraine in adults.

Emgality

Migraine

Emgality is indicated for the preventive treatment of migraine in adults

Cluster Headache

Emgality is indicated for the treatment of episodic cluster headache in adults

Vyepti

Vyepti is indicated for the preventive treatment of migraine in adults.

COVERAGE CRITERIA

Preventive Treatment of Migraine

Authorization may be granted when the requested drug is being prescribed for the preventive treatment of migraine in an adult patient when ALL of the following criteria are met:

- The request is for Aimovig, Ajovy, Emgality 120 mg, or Vyepti
- The patient has NOT received at least 3 months of treatment with the requested drug

CGRP Receptor Antagonists Inj IV PA with Limit 2581-C UDR 06-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

Episodic Cluster Headache

Authorization may be granted when the requested drug is being prescribed for the treatment of episodic cluster headache in an adult patient when ALL of the following criteria are met:

- The request is for Emgality 100 mg
- The patient has NOT received at least 3 weeks treatment with the requested drug
- The patient meets ONE of the following:
 - The patient experienced an inadequate treatment response to sumatriptan (nasal or subcutaneous) OR zolmitriptan (nasal or oral)
 - The patient experienced an intolerance to, or the patient has a contraindication to sumatriptan (nasal or subcutaneous) OR zolmitriptan (nasal or oral)

CONTINUATION OF THERAPY

Preventive Treatment of Migraine

Authorization may be granted when the requested drug is being prescribed for the preventive treatment of migraine in an adult patient when ALL of the following criteria are met:

- The request is for Aimovig, Ajovy, Emgality 120 mg, or Vyepi
- The patient has received at least 3 months of treatment with the requested drug
- The patient had a reduction in migraine days per month from baseline

Episodic Cluster Headache

Authorization may be granted when the requested drug is being prescribed for the treatment of episodic cluster headaches in an adult patient when ALL of the following criteria are met:

- The request is for Emgality 100 mg
- The patient has received at least 3 weeks of treatment with the requested drug
- The patient had a reduction in weekly cluster headache attack frequency from baseline

QUANTITY LIMITS APPLY

<u>QUANTITY LIMIT</u>		
<u>Migraine:</u>		
Drug	1 Month Limit*	3 Month Limit*
Aimovig 70 mg, 140 mg (erenumab-aooe injection)	1 mL (1 autoinjector x 1 mL each) / 25 days	3 mL (3 autoinjectors x 1 mL each) / 75 days
Ajovy 225 mg (fremanezumab-vfrm injection)	4.5 mL (3 autoinjectors or syringes x 1.5 mL each) / 75 days	4.5 mL (3 autoinjectors or syringes x 1.5 mL each) / 75 days
Emgality 120 mg (galcanezumab-gnlm injection)		
LOADING DOSE Loading dose quantity applies to new starts of therapy (i.e., patient has not filled a prescription for Emgality in the past 180 days).	2 mL (2 syringes or pens x 1 mL each) / 25 days	4 mL (4 syringes or pens x 1 mL each) / 75 days
MAINTENANCE DOSE	1 mL (1 syringe or pen x 1 mL each) / 25 days	3 mL (3 syringes or pens x 1 mL each) / 75 days

CGRP Receptor Antagonists Inj IV PA with Limit 2581-C UDR 06-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

Maintenance dose applies to those not new to therapy (i.e., patient has filled a prescription for Emgality in the past 180 days).		
Vyepti 100 mg (eptinezumab-jjmr injection, for intravenous use)	3 mL (3 single dose vials x 1 mL each) / 75 days	3 mL (3 single dose vials x 1 mL each) / 75 days
Cluster Headache:		
Drug	1 Month Limit*	3 Month Limit*
Emgality 100 mg (galcanezumab-gnlm injection)	3 mL (3 syringes x 1 mL each) / 25 days	9 mL (9 syringes x 1 mL each) / 75 days
*The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.		

DURATION OF APPROVAL (DOA)

2581-C:

- Aimovig, Ajovy, Emgality 120 mg, Vyepti (Migraine Prevention): Initial therapy DOA: 3 months; Continuation of therapy DOA: 12 months
- Emgality 100 mg (Cluster Headache): Initial therapy DOA: 1 month; Continuation of therapy DOA: 12 months
- REG 3160-C:
 - Aimovig, Ajovy, Emgality 120 mg, Vyepti (Migraine Prevention) DOA: 12 months
 - Emgality 100 mg (Cluster Headache): Initial therapy DOA: 1 month; Continuation of therapy DOA: 12 months

REFERENCES

1. Aimovig [package insert]. Thousand Oaks, CA: Amgen Inc; May 2023.
2. Ajovy [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc: October 2022.
3. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; March 2021.
4. Vyepti [package insert]. Bothell, WA: Lundbeck Seattle Bio Pharmaceuticals, Inc; October 2022.
5. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed April 11, 2024.
6. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 04/11/2024).
7. Silberstein S, Holland S, Freitag F, et al. Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality and the American Headache Society Standards Subcommittee of the American Academy of Neurology. *Neurology* 2012;78:1337-1345.
8. Silberstein S, Holland S, Freitag F, et al. Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality and the American Headache Society Standards Subcommittee of the American Academy of Neurology. *Neurology* 2013;80:871
9. American Academy of Neurology. Update: Pharmacologic Treatments for Episodic Migraine Prevention in Adults. Available at: <https://www.aan.com/Guidelines/Home/GetGuidelineContent/545>. Accessed April 2024.
10. Ailani J, Burch RC, Robbins MS et al. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. *Headache*. 2021; 61:1021-1039.
11. Charles A, Digre K, Goadsby P, et al. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. *Headache*. 2024; 00:1-9.
12. American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice. *Headache* 2019; 59:1-18.
13. Robbins M, et al. Treatment of Cluster Headache: The American Headache Society Evidence Based Guidelines. *Headache* 2016;56:1093-1106.
14. Francis G, et al. Acute and preventive pharmacologic treatment of cluster headache. *American Academy of Neurology. Neurology* 2010; 463-473.

CGRP Receptor Antagonists Inj IV PA with Limit 2581-C UDR 06-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

Written by: UM Development (TM/JK)
 Date written: 05/2018
 Revised: 07/2018 (no clinical changes), 08/2018 (add 7, revise 5&6), 09/2018 (add Ajovy), (add Emgality), 10/2018 (trial of 1, remove Botox), 03/2019 (add 140mg Aimovig); (MAC) 06/2019 (added indication for Emgality), 06/2019 (removed MDC designation, no clinical changes); (JK) 08/2019 (Created REG 3160-C for regulation about DOA); (TM) 02/2020 (added Vyepti); (MAC) 04/2020 (added Ajovy autoinjector, updated document name/title), 06/2020 (no clinical changes), 06/2021 (updated duplication of therapy question); (TM) 05/2022 (update Aimovig QL); (KMB) 06/2023 (no clinical changes), 05/2024 (removed step for migraine prevention), 08/2024 (removed concurrent CGRP exclusion)
 Reviewed: Medical Affairs (EPA) 05/2018, (EPA) 09/2018, (EPA) 10/2018, 10/2018, (GD) 03/2019, (CHART) 08/29/2019, (CHART) 03/12/20, (CHART) 04/30/20, (CHART) 06/25/20, (CHART) 10/8/2020, 07/01/2021, 06/30/2022, 06/01/2023, 05/30/2024, 08/29/2024
 External Review: 05/2018, 10/2018, 04/2019 (FYI), 10/2019, 03/2020, 06/2020 (FYI), 10/2020, 10/2021, 10/2022, 10/2023, 10/2024, 10/2024 (FYI)

CRITERIA FOR APPROVAL

1	Is the requested drug being prescribed for the preventive treatment of migraine in an adult patient? [If Yes, then go to 2. If No, then go to 10.]	Yes	No
2	Has the patient received at least 3 months of treatment with the requested drug? [If Yes, then go to 3. If No, then go to 6.]	Yes	No
3	Is this request for any of the following: A) Aimovig, B) Ajovy, C) Emgality 120 mg, D) Vyepti? [If Yes, then go to 4. If No, then no further questions.]	Yes	No
4	Has the patient had a reduction in migraine days per month from baseline? [If Yes, then go to 5. If No, then no further questions.]	Yes	No
5	Does the patient require MORE than the plan allowance of any of the following: A) 1 injection (70 mg or 140 mg) per month of Aimovig, B) 3 injections (225 mg each) per 3 months of Ajovy, C) 1 injection (120 mg) per month of Emgality, D) 3 single dose vials (100 mg each) for intravenous infusion per 3 months of Vyepti? [No further questions]	Yes	No
RPH Note: If yes, then deny and enter a partial approval per Quantity Limit Chart.			
6	Is this request for any of the following: A) Aimovig, B) Ajovy, C) Vyepti? [If Yes, then go to 7. If No, then go to 8.]	Yes	No
7	Does the patient require MORE than the plan allowance of any of the following: A) 1 injection (70 mg or 140 mg) per month of Aimovig, B) 3 injections (225 mg each) per 3 months of Ajovy, C) 3 single dose vials (100 mg each) for intravenous infusion per 3 months of Vyepti? [No further questions]	Yes	No
RPH Note: If yes, then deny and enter a partial approval per Quantity Limit Chart			
8	Is this request for Emgality 120 mg? [If Yes, then go to 9. If No, then no further questions.]	Yes	No

CGRP Receptor Antagonists Inj IV PA with Limit 2581-C UDR 06-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

9	Does the patient require MORE than the plan allowance of 4 injections (120 mg each) per first 3 months of Emgality (i.e., loading dose of 2 injections followed by 1 injection per month)? [No further questions]	Yes	No
	RPH Note: If yes, then deny and enter a partial approval for Emgality 120 mg: 4 mL (4 syringes or pens x 1 mL each) per 75 days*.		
10	Is this request for Emgality 100 mg for the treatment of episodic cluster headache in an adult patient? [If Yes, then go to 11. If No, then no further questions.]	Yes	No
11	Has the patient received at least 3 weeks of treatment with the requested drug? [If Yes, then go to 12. If No, then go to 14.]	Yes	No
12	Has the patient had a reduction in weekly cluster headache attack frequency from baseline? [If Yes, then go to 13. If No, then no further questions.]	Yes	No
13	Does the patient require MORE than the plan allowance of 3 injections (100 mg each) per month of Emgality? [No further questions]	Yes	No
	RPH Note: If yes, then deny and enter a partial approval for Emgality 100 mg: 3 mL (3 syringes x 1 mL each) per 25 days* OR 9 mL (9 syringes x 1 mL each) per 75 days*		
14	Has the patient experienced an inadequate treatment response to ANY of the following: A) sumatriptan (nasal or subcutaneous), B) zolmitriptan (nasal or oral)? [If Yes, then go to 16. If No, then go to 15.]	Yes	No
15	Has the patient experienced an intolerance to or does the patient have a contraindication to ANY of the following: A) sumatriptan (nasal or subcutaneous), B) zolmitriptan (nasal or oral)? [If Yes, then go to 16. If No, then no further questions.]	Yes	No
16	Does the patient require MORE than the plan allowance of 3 injections (100 mg each) per month of Emgality? [No further questions]	Yes	No
	RPH Note: If yes, then deny and enter a partial approval for Emgality 100 mg: 3 mL (3 syringes x 1 mL each) per 25 days*		

Mapping Instructions			
	Yes	No	DENIAL REASONS
1.	Go to 2	Go to 10	
2.	Go to 3	Go to 6	
3.	Go to 4	Deny	Your plan only covers this drug when it is used for certain health conditions. Covered use for Aimovig, Ajovy, Emgality 120 mg and Vyepti is for preventative treatment of migraine in adults. Your plan does not cover this drug for your health condition that your doctor told us you have. We reviewed

			<p>the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Diagnosis - Aimovig, Ajovy, Emgality 120 mg, Vyepti]</p>
4.	Go to 5	Deny	<p>Your plan only covers this drug if it works well for you. We have denied your request because the drug did not work well for you. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Continuation: Efficacy]</p>
5.	[Please select the appropriate denial close option. RPh Note: For the denial verbiage, only include the requested drug. Remove all the other drugs from the verbiage]. Deny	[PA Approved for 12 months. See Quantity Limit Chart]. Approve, 12 Months	<p>We have denied your request because it is for more than the amount your plan covers (quantity limit). We reviewed the information we had. We have partially approved your request for this drug up to the amount your plan covers A) 1 autoinjector per month of Aimovig 70 mg, 140 mg, B) 3 autoinjectors or syringes per 3 months of Ajovy 225 mg, C) 1 syringe or pen per month of Emgality 120 mg, or D) 3 single dose vials per 3 months of Vyepti 100 mg. Your request for more drug has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Quantity, Exceeds max limit, Partial denial – Continuation, Migraine]</p>
6.	Go to 7	Go to 8	
7.	[Please select the appropriate denial close option. RPh Note: For the denial verbiage, only include the requested drug. Remove all the other drugs from the verbiage]. Deny	[PA Approved for 3 months. See Quantity Limit Chart]. Approve, 3 Months	<p>We have denied your request because it is for more than the amount your plan covers (quantity limit). We reviewed the information we had. We have partially approved your request for this drug up to the amount your plan covers A) 1 autoinjector per month of Aimovig 70 mg, 140 mg, B) 3 autoinjectors or syringes per 3 months of Ajovy 225 mg, C) 3 single dose vials per 3 months of Vyepti 100 mg. Your request for more drug has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review</p> <p>[Short Description: Quantity, Exceeds max limit, Partial denial – Initial, Migraine - Aimovig, Ajovy, Vyepti]</p>
8.	Go to 9	Deny	<p>Your plan only covers this drug when it is used for certain health conditions. Covered use for Aimovig, Ajovy, Vyepti and Emgality 120 mg is for</p>

			<p>preventative treatment of migraine in adults. Your plan does not cover this drug for your health condition that your doctor told us you have. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Diagnosis - Aimovig, Ajovy, Vyepti, Emgality 120 mg]</p>
9.	Deny	[PA Approved for 3 months. Approve Emgality 120 mg: 4 mL (4 syringes or pens x 1 mL each) per 75 days]. Approve, 3 Months	<p>We have denied your request because it is for more than the amount your plan covers (quantity limit). We reviewed the information we had. We have partially approved your request for this drug up to the amount your plan covers (4 syringes or pens per first 3 months then 1 injection per month of Emgality 120 mg). Your request for more drug has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Quantity, Exceeds max limit, Partial denial – Initial, Migraine - Emgality]</p>
10.	Go to 11	Deny	<p>Your plan only covers this drug when it is used for certain health conditions. Covered uses are for preventive treatment of migraine and treatment of cluster headaches in an adult. Your plan does not cover this drug for your health condition that your doctor told us you have. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Diagnosis - all]</p>
11.	Go to 12	Go to 14	
12.	Go to 13	Deny	<p>Your plan only covers this drug if it works well for you. We have denied your request because the drug did not work well for you. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review.</p> <p>[Short Description: Continuation: Efficacy]</p>
13.	Deny	[PA Approved for 12 months. Approve Emgality 100 mg: 3 mL (3 syringes x 1mL each)]	<p>We have denied your request because it is for more than the amount your plan covers (quantity limit). We reviewed the information we had. We have partially approved your request for this drug up to the amount your plan covers (3 syringes per month of Emgality 100 mg). Your request for more drug has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also</p>

		per 25 days* OR 9 mL (9 syringes x 1 mL each) per 75 days*]. Approve, 12 Months	request other plan documents for your review. [Short Description: Quantity, Exceeds max limit, Partial denial - Cluster]
14.	Go to 16	Go to 15	
15.	Go to 16	Deny	Your plan only covers this drug if you have tried other drugs and they did not work well for you. We have denied your request because: A) You have not tried sumatriptan (nasal or subcutaneous) or zolmitriptan (nasal or oral), and B) You do not have a medical reason not to take them. We reviewed the information we had. Your request has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review. [Short Description: Step therapy – Cluster]
16.	Deny	[PA Approved for 1 month. Approve Emgality 100 mg: 3 mL (3 syringes x 1 mL each) per 25 days*]. Approve, 1 Months	We have denied your request because it is for more than the amount your plan covers (quantity limit). We reviewed the information we had. We have partially approved your request for this drug up to the amount your plan covers (3 syringes per month of Emgality 100 mg). Your request for more drug has been denied. Your doctor can send us any new or missing information for us to review. For this drug, you may have to meet other criteria. You can request the drug policy for more details. You can also request other plan documents for your review. [Short Description: Quantity, Exceeds max limit, Partial denial - Cluster]